Should alectinib or ceritinib be given as first line therapy for ALK positive non-small cell lung cancer patients instead of crizotinib?

Godefridus J. Peters*, Ittai B. Muller, Elisa Giovannetti

*Corresponding author for this work

Research output: Contribution to journalEditorialAcademicpeer-review

Original languageEnglish
Pages (from-to)S1010-S1013
JournalTranslational Cancer Research
Volume6
DOIs
Publication statusPublished - 1 Aug 2017

Cite this